Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics
暂无分享,去创建一个
B. Gloss | G. Ahlenstiel | A. Nagrial | M. Carlino | Joey Lai | S. Read | B. Gao | Li Ma | H. Mahajan | D. Shek | Matteo S. Carlino | Bo Gao | Dmitrii Shek | Brian Gloss | Joey Lai | Hui E. Zhang | Hema Mahajan | Adnan Nagrial | Li Ma | Hui E. Zhang
[1] R. Vento-Tormo,et al. An introduction to spatial transcriptomics for biomedical research , 2022, Genome Medicine.
[2] L. Pachter,et al. Museum of spatial transcriptomics , 2020, Nature Methods.
[3] N. Girard,et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] G. Ahlenstiel,et al. Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes , 2021, Cancers.
[5] Raphael Gottardo,et al. Spatial transcriptomics at subspot resolution with BayesSpace , 2021, Nature Biotechnology.
[6] G. Ahlenstiel,et al. Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates. , 2021, The oncologist.
[7] Xing Huang,et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy , 2021, Signal Transduction and Targeted Therapy.
[8] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[9] V. Marx. Method of the Year: spatially resolved transcriptomics , 2021, Nature Methods.
[10] Raphael Gottardo,et al. Integrated analysis of multimodal single-cell data , 2020, Cell.
[11] X. Solé,et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification , 2019, Journal for ImmunoTherapy of Cancer.
[12] S. O’Donoghue,et al. Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype. , 2021, Cell reports.
[13] C. Robert. A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.
[14] Joseph Bergenstråhle,et al. Spatially Resolved Transcriptomes—Next Generation Tools for Tissue Exploration , 2020, BioEssays : news and reviews in molecular, cellular and developmental biology.
[15] J. Larkin,et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] E. Taioli,et al. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use , 2020, Translational lung cancer research.
[17] O. Molinier,et al. Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial , 2019, Clinical Cancer Research.
[18] Barbara B. Shih,et al. Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors , 2018, Cancer Immunology Research.
[19] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[20] F. Gemignani,et al. Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. , 2018, Journal of thoracic disease.
[21] Ross A Soo,et al. De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.
[22] M. Suarez‐Almazor,et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.
[23] N. Agarwal,et al. Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers , 2017, Front. Oncol..
[24] Jaakko Astola,et al. Generalized Hampel Filters , 2016, EURASIP J. Adv. Signal Process..
[25] T. Barnetche,et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.